Q2 2026 results exceeded expectations with strong non-COVID revenue growth, robust performance from acquired products, and continued R&D progress. Full-year revenue guidance was raised, cost savings initiatives expanded, and the dividend commitment reaffirmed.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.